Abstract:
AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3 and CYP3A5*6. Standard pairwise genetic distances, locus-specific and global Fst statistics were calculated. RESULTS:CYP allele and genotype frequencies demonstrated significant variability. Overall, the degree of between-population variance displayed by CYP SNPs was lower than that recorded from neutral short tandem repeats and Alu-insertion polymorphism, indicating evolutionary conservation of CYP polymorphisms. CYP-based genetic distances were well correlated with the geographic distances across populations (r = 0.822, p = 0.008). CONCLUSIONS:Although the tested variants were present in the neighboring, yet secluded, populations at the expected range of frequencies, the observed frequencies were significantly variable across Eurasian populations, indicating potential relevance to clinical decision making.
journal_name
Pharmacogenomicsjournal_title
Pharmacogenomicsauthors
Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman Idoi
10.2217/14622416.9.7.847subject
Has Abstractpub_date
2008-07-01 00:00:00pages
847-68issue
7eissn
1462-2416issn
1744-8042journal_volume
9pub_type
杂志文章相关文献
PHARMACOGENOMICS文献大全abstract::The response to stress triggers transcriptional activation of genes involved in cell survival and/or cell death. Thus, the monitoring of gene expression levels in large gene sets or whole genomes in response to various agents (toxicogenomics) has been proposed as a tool for investigating mechanisms of toxicity. Althou...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.6.4.419
更新日期:2005-06-01 00:00:00
abstract::Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs-2016-0055
更新日期:2016-07-01 00:00:00
abstract:AIM:To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. PATIENTS & METHODS:In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on stati...
journal_title:Pharmacogenomics
pub_type: 杂志文章,meta分析
doi:10.2217/pgs.16.8
更新日期:2016-04-01 00:00:00
abstract::The emergence of antibiotic resistance and multi-drug resistance in bacterial pathogens underscores the need for the development of novel classes of antibiotics. The availability of complete genome sequence data from many important human pathogens provides a wealth of fundamental information. This allows us to define ...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.3.3.315
更新日期:2002-05-01 00:00:00
abstract::Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.7.4.633
更新日期:2006-06-01 00:00:00
abstract:AIM:We conducted a genome-wide association study using the Illumina Exome Array to identify coding SNPs that may explain additional warfarin dose variability. PATIENTS & METHODS:Analysis was performed after adjustment for clinical variables and genetic factors known to influence warfarin dose among 1680 warfarin users...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2017-0046
更新日期:2017-07-01 00:00:00
abstract::Recently, the USA FDA has made a labeling change to the drug information contained in carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, the FDA recommends genotyping all Asians for the alle...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.9.10.1543
更新日期:2008-10-01 00:00:00
abstract::Individuals with neuropsychiatric diseases have epigenetic programming disturbances, both in the brain, which is the primary affected organ, and in secondary tissues. Epigenetic modulations are molecular modifications made to DNA, RNA and proteins that fine-tune genotype into phenotype and do not include DNA base chan...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.12.1809
更新日期:2008-12-01 00:00:00
abstract::miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.8.8.971
更新日期:2007-08-01 00:00:00
abstract:AIM:To determine the accuracy of international warfarin pharmacogenetic algorithms developed on large multiethnic cohorts (comprising more than 1000 subjects) to predict therapeutic warfarin doses in Turkish patients. MATERIALS & METHODS:We investigated two Turkish warfarin-treated cohorts: patients with no history of...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.58
更新日期:2015-01-01 00:00:00
abstract:AIM:Tamoxifen is one of the most commonly used endocrine therapeutic agents for breast cancer. Although many studies have examined whether the treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype, the study results have been inconsistent, and the role of CYP2D6 in the prediction of pati...
journal_title:Pharmacogenomics
pub_type: 杂志文章,meta分析
doi:10.2217/pgs.13.221
更新日期:2014-01-01 00:00:00
abstract:OBJECTIVES:The objective of this study was to assess the utility of the gene expression profiling technique for the preclinical evaluation of drug efficacy and safety, taking a new therapeutic approach for Duchenne muscular dystrophy (DMD) as an example. METHODS:Muscles from dystrophin-deficient (mdx) mice, a well-cha...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/14622416.7.3.281
更新日期:2006-04-01 00:00:00
abstract::The NIH initiated the PharmGKB in April 2000. The primary mission was to create a repository of primary data, tools to track associations between genes and drugs, and to catalog the location and frequency of genetic variations known to impact drug response. Over the past 10 years, new technologies have shifted researc...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.10.15
更新日期:2010-04-01 00:00:00
abstract::Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.8.8.1081
更新日期:2007-08-01 00:00:00
abstract::For the last 40 years, 5-fluorouracil (5-FU) has remained the treatment of choice in both the adjuvant and advanced treatment of colorectal cancer (CRC). However, 5-FU monotherapy produces response rates of only 10-20% in the advanced setting. 5-FU has been combined with newer agents, such as oxaliplatin and irinoteca...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.6.6.603
更新日期:2005-09-01 00:00:00
abstract::Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.12.113
更新日期:2012-09-01 00:00:00
abstract::The polymorphism CYP1A2*1F of the cytochrome 1A2 gene affects the inducibility of this cytochrome, which is involved in the metabolism of many commonly used drugs. We developed a rapid-cycle polymerase chain reaction (PCR) and fluorescent probe melting curve analysis on the LightCycler instrument for identification of...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/phgs.4.5.643.23798
更新日期:2003-09-01 00:00:00
abstract::Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.9.2.215
更新日期:2008-02-01 00:00:00
abstract:AIMS: AMPD1 c.34C > T (rs17602729) polymorphism results in AMPD1 deficiency. We examined the association of AMPD1 deficiency and variability of hemodynamic response to regadenoson. SUBJECTS & METHODS:Genotyping for c.34C>T was performed in 267 patients undergoing regadenoson cardiac stress testing. RESULTS:Carriers o...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.15.116
更新日期:2015-11-01 00:00:00
abstract:AIMS:S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. MATERIALS & METHODS:Chemonaive patients received S-1 40 mg/...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.09.48
更新日期:2009-07-01 00:00:00
abstract::Related to many drug gene-product interactions, application of pharmacogenomics can lead to improved medication efficacy while decreasing or avoiding adverse drug reactions. However, utilizing pharmacogenomics without other information does not allow for optimal medication therapy. Currently, there is a lack of docume...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2015-0015
更新日期:2016-05-01 00:00:00
abstract::The narrow therapeutic range and wide interpatient variability in dose requirement make anticoagulation response to coumarin derivatives unpredictable. As a result, patients require frequent monitoring to avert adverse effects and maintain therapeutic efficacy. Polymorphisms in VKORC1 and CYP2C9 jointly account for ab...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.2217/pgs.09.125
更新日期:2009-10-01 00:00:00
abstract:UNLABELLED:Aim & patients & methods: This study investigated 24-h pharmacokinetic and CYP3A5 pharmacogenetic differences between once-daily tacrolimus (Tac-q.d.) versus twice-daily tacrolimus (Tac-b.i.d.) pretransplantation and at 1 month and 1 year post-transplantaion. RESULTS:The dose-adjusted trough level (Cmin) an...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.98
更新日期:2014-08-01 00:00:00
abstract::RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.1517/14622416.1.2.187
更新日期:2000-05-01 00:00:00
abstract::Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly effective pharmacological symptomatic treatment is available. The marked variability in drug response and in adverse profiles associated with this treatment led to the search of genetic markers associated with these features. We pres...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs.14.93
更新日期:2014-06-01 00:00:00
abstract::Discovery Partners International (Nasdaq: DPII) is a leader in collaborative drug discovery. DPI's integrated discovery framework encompasses a broad spectrum of capabilities in chemistry, biology, informatics, computational modeling and synthesis automation. DPI's approach to drug discovery places a heavy emphasis on...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.1517/14622416.3.1.145
更新日期:2002-01-01 00:00:00
abstract::Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...
journal_title:Pharmacogenomics
pub_type: 杂志文章
doi:10.2217/pgs-2020-0120
更新日期:2021-01-01 00:00:00
abstract::Referred to as the micromanagers of gene expression, microRNAs (miRNAs) are evolutionarily conserved small noncoding RNAs. Polymorphisms in the miRNA pathway (miR-polymorphisms) are emerging as powerful tools to study the biology of a disease and have the potential to be used in disease prognosis and diagnosis. Detect...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/14622416.10.3.399
更新日期:2009-03-01 00:00:00
abstract::The successful application of pharmacogenetics in routine clinical practice is still a long way from becoming a reality. In order to favor the transfer of pharmacogenetic results to clinical practice, especially in psychiatry, these studies must be optimized. This article reviews the strengths and weaknesses that char...
journal_title:Pharmacogenomics
pub_type: 杂志文章,多中心研究,评审
doi:10.2217/pgs.12.159
更新日期:2012-11-01 00:00:00
abstract::Skeletal muscle toxicity is the primary adverse effect of statins. In this review, we summarize current knowledge regarding the genetic and nongenetic determinants of risk for statin induced myopathy. Many genetic factors were initially identified through candidate gene association studies limited to pharmacokinetic (...
journal_title:Pharmacogenomics
pub_type: 杂志文章,评审
doi:10.2217/pgs.12.11
更新日期:2012-04-01 00:00:00